Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29552577
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\29552577
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Mol+Ther+Methods+Clin+Dev
2018 ; 8
(ä): 210-221
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
The Pharmacology of T Cell Therapies
#MMPMID29552577
Milone MC
; Bhoj VG
Mol Ther Methods Clin Dev
2018[Mar]; 8
(ä): 210-221
PMID29552577
show ga
Adoptive cellular therapy using T cells with tumor specificity derived from
either natural T cell receptors (TCRs) or an artificial chimeric antigen receptor
(CAR) has reached late phase clinical testing, with two CAR T cell therapies
achieving regulatory approval within the United States in 2017. The effective use
of these therapies depends upon an understanding of their pharmacology, which is
quite divergent from traditional small molecule or biologic drugs. We review the
different types of T cell therapy under clinical development, the factors
affecting cellular kinetics following infusion, and the relationship between
these cellular kinetics and anti-cancer activity. We also discuss the toxicity
associated with T cell therapies, with an emphasis on cytokine release syndrome
and neurotoxicity, and the gaps in knowledge regarding these frequent and unique
adverse effects.